Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletionEsther N. Oliva, Roberto Latagliata, Agostino Cortelezzi et al.|European Journal Of Haematology|2010Cited by 29
Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther Natalie Olíva, Roberto Latagliata, Michael Lauseker et al.|Cancer Medicine|2015Cited by 23
Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)Esther Natalie Olíva, Francesco Nobile, Valeria Santini et al.|Blood|2012Cited by 18
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, TrialEsther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|Blood|2015Cited by 13